# Denifanstat PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/denifanstat

> The next catalyst for denifanstat, sponsored by Sagimet Biosciences Inc. (SGMT), is its primary completion, August 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | denifanstat |
| Codes | TVB-2640 |
| Sponsor | Sagimet Biosciences Inc. (SGMT) https://sec-api.dev/companies/sgmt/catalysts |
| Indications | moderate to severe acne in oct 2026, moderate to severe acne in china, moderate to severe acne in oct 2026 november 2026 29, [Acne Vulgaris](https://sec-api.dev/indications/acne-vulgaris) |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track |

## Timeline

### May 2023: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2025-03-12, last confirmed 2025-03-12.
- SEC Form 10-K (accession 0001558370-25-002747): "In May 2023, Ascletis Pharma, announced positive topline results with the achievement of primary and key secondary endpoints in a Phase 2 clinical trial in 179 patients with moderate to severe acne vulgaris in China." https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/sgmt-20241231x10k.htm

### Jan 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2024-11-14, last confirmed 2026-10-01.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-022763): "January 2024, Sagimet announced positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or" https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_ex99-1.htm
- SEC prospectus (424B) (accession 0001193125-26-409325): "In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000119312526409325/d68394d424b5.htm
- SEC prospectus (424B) (accession 0001104659-26-049662): "In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000110465926049662/tm2612738-3_424b5.htm
- SEC prospectus (424B) (accession 0001104659-25-078746): "In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial, evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000110465925078746/tm2523529-1_424b5.htm
- SEC Form 10-Q (accession 0001558370-25-006836): "In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000155837025006836/sgmt-20250331x10q.htm
- SEC Form 10-K (accession 0001558370-25-002747): "In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/sgmt-20241231x10k.htm
- SEC Form 10-K (accession 0001558370-25-002747): "In January 2024, the Company announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/sgmt-20241231x10k.htm
- SEC Form 10-Q (accession 0001558370-24-015623): "In January 2024, the Company announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000155837024015623/sgmt-20240930x10q.htm
- SEC Form 10-Q (accession 0001558370-24-015623): "In January 2024, we announced positive topline results from the Phase 2b FASCINATE-2 clinical trial evaluating denifanstat in 168 biopsy-confirmed MASH patients with stage F2 or F3 fibrosis compared to placebo at week 52." https://www.sec.gov/Archives/edgar/data/1400118/000155837024015623/sgmt-20240930x10q.htm
- SEC Form 10-K (accession 0001558370-25-002747): "In January 2024, we announced positive topline results at week 52 from our Phase 2b FASCINATE-2 clinical trial." https://www.sec.gov/Archives/edgar/data/1400118/000155837025002747/sgmt-20241231x10k.htm
- SEC Form 10-K (accession 0001104659-26-026140): "In January 2024, we announced positive topline results at week 52 from our Phase 2b FASCINATE-2 clinical trial." https://www.sec.gov/Archives/edgar/data/1400118/000110465926026140/sgmt-20251231x10k.htm

### Q2 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2024-11-14, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045791): "Topline results expected in 2Q2025" https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045791): "In November 2024, the Company's license partner for China, Ascletis BioScience Co. Ltd. (Ascletis) announced completion of enrollment of 480 patients in its Phase 3 clinical trial of denifanstat for acne in China, and that it expects to announce topline results in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-022763): "In November 2024, the Company's license partner for Greater China, Ascletis BioScience Co. Ltd. (Ascletis) announced completion of enrollment of 480 patients in its Phase 3 clinical trial of denifanstat for acne in China, and that it expects to announce topline results in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-118342): "(Ascletis) announced completion of enrollment of 480 patients in its Phase 3 clinical trial of denifanstat for acne in China, and that it expects to announce topline results in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1400118/000110465924118342/tm2428394d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-022763): "Acne Phase 3 trial enrollment completed in Nov 2024; topline results expected in 2Q2025" https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-014099): "Acne Phase 3 trial enrollment completed in Nov 2024; topline results expected in 2Q2025" https://www.sec.gov/Archives/edgar/data/1400118/000110465925014099/tm256733d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-000137): "Acne Phase 3 study enrollment completed in Nov 2024; topline results expected in 2Q2025" https://www.sec.gov/Archives/edgar/data/1400118/000110465925000137/tm2431774d1_ex99-1.htm

### Jun 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-08-13, last confirmed 2026-03-11.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-026146): "Phase 2 trial design anticipated to be informed by the results of the Phase 1 trial, expect a 12 - week dose ranging study in moderate to severe acne patients with lesion reduction, treatment success (IGA) as endpoints Phase 1 trial initiated in June 2025 Goal to initiate Phase 2 trial in 2026, subject to consultation with regulatory authorities and outcome of Phase 1 trial" https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "Phase 2 trial design will be informed by the results of the Phase 1 trial, anticipate a 12 - week dose ranging study in moderate to severe acne patients with lesion reduction, treatment success (IGA) as endpoints Phase 1 trial initiated in June 2025 Goal to initiate Phase 2 trial in 2026, subject to consultation with regulatory authorities and outcome of Phase 1 trial" https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Phase 2 trial design will be informed by the results of the Phase 1 trial, anticipate a 12 - week dose ranging study in moderate to severe acne patients with lesion reduction, treatment success (IGA) as endpoints Phase 1 trial initiated in June 2025 Goal to initiate Phase 2 trial in 2026, subject to consultation with regulatory authorities and outcome of Phase 1 trial" https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-2.htm

### 2H 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-08-13, last confirmed 2025-08-13.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Additionally, pending consultation with regulatory authorities, we plan to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of our FASN inhibitor denifanstat and resmetirom in the second half of 2025 as the first step towards development of a combination product for patients living with MASH." https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-1.htm

### late 2025: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-12-17, last confirmed 2025-12-17.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-121819): "Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025" https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-121819): "Topline data from this trial are anticipated by the end of 2025 and, if positive, are planned to be used to advance the development of the combination for F4 patients living with metabolic dysfunction-associated steatohepatitis (MASH)" https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_ex99-1.htm

### Sep 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2025-11-13, last confirmed 2025-12-17.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-121819): "September 2025, Sagimet announced that it has dosed the first participants in a Phase 1 PK trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agonist, resmetirom." https://www.sec.gov/Archives/edgar/data/1400118/000110465925121819/tm2533462d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "In September 2025, Sagimet dosed the first participants in a Phase 1 pharmacokinetic (PK) trial of a combination of its oral once-daily fatty acid synthase (FASN) inhibitor, denifanstat, and a thyroid hormone receptor beta (THR-β) agonist, resmetirom." https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "Primary endpoint: liver biopsies Potential Clinical Development Program for Denifanstat and Resmetirom Combination Phase 1 started in September 2025 Phase 2 trial design will be informed by the results of the Phase 1 trial" https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-2.htm

### Jan 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3. Indication: moderate to severe acne in China.
- First seen 2026-04-27, last confirmed 2026-04-28.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-048971): "January 2026, positive topline results were reported in the open-label Phase 3 trial (n=240) evaluating the long-term safety of 50 mg once-daily denifanstat in patients with moderate to severe acne in China by Sagimet's license partner Ascletis Bioscience Co." https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_ex99-2.htm
- SEC prospectus (424B) (accession 0001104659-26-049662): "In January 2026, our license partner for China, Ascletis BioScience Co. Ltd. (Ascletis), a subsidiary of Ascletis Pharma Inc. (Ascletis Pharma), reported positive topline results in the open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne in China." https://www.sec.gov/Archives/edgar/data/1400118/000110465926049662/tm2612738-3_424b5.htm

### 1H 2026: topline data readout

- Status: scheduled. Date confidence: half. Stage: 1.
- First seen 2025-05-08, last confirmed 2025-11-13.
- SEC Form 10-Q (accession 0001104659-25-110846): "We anticipate topline data from this Phase 1 PK trial to be available in the first half of 2026 and plan to use it to inform the optimal dose levels of denifanstat and resmetirom to evaluate in a Phase 2 combination proof-of-concept efficacy trial in F4 MASH patients, subject to consultation with regulatory authorities." https://www.sec.gov/Archives/edgar/data/1400118/000110465925110846/sgmt-20250930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a co mbination of denifanstat and resmetirom initiated in September 2025 ; data readout expected 1H 2026 Denifanstat in MASH TVB - 3567 in Acne" https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a combination of denifanstat and resmetirom initiated in September 2025; data readout expected 1H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-110852): "Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a combi nation of denifanstat and resmetirom initiated in September 2025; data readout expected 1H 2026 Denifanstat in MASH TVB - 3567 in Acne" https://www.sec.gov/Archives/edgar/data/1400118/000110465925110852/tm2530949d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-101819): "Phase 1 clinical trial to evaluate the pharmacokinetics (PK) and tolerability of a combination of denifanstat and resmetirom initiated in September 2025; data readout expected 1H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465925101819/tm2529317d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Sagimet plans to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of denifanstat and resmetirom in the second half of 2025, with an anticipated data readout in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a co mbination of denifanstat and resmetirom planned to initiate in 2H 2025; data readout expected 1H 2026 Denifanstat in MASH TVB - 3567 in Acne" https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a combination of denifanstat and resmetirom planned to initiate in 2H 2025; data readout expected 1H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-077200): "Phase 1 clinical trial to evaluate the pharmacokinetics ථ (PK) and tolerability of a combi nation of denifanstat and resmetirom planned to initiate in 2H 2025; data readout expected 1H 2026 Denifanstat in MASH TVB - 3567 in Acne" https://www.sec.gov/Archives/edgar/data/1400118/000110465925077200/tm2523275d1_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-045791): "Building on this combination data, subject to consultation with regulatory authorities, Sagimet plans to initiate a Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom in the second half of 2025, with an anticipated data readout in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1400118/000110465925045791/tm2514358d1_ex99-1.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 2.
- First seen 2026-04-27, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "Plan to initiate Phase 2 clinical trial before the end of 2026" https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-408224): "Upon completion of Phase 1 clinical trial, plan to consult with regulatory authorities regarding Phase 2 clinical trial design, with goal of initiating Phase 2 clinical trial before the end of 2026 •" https://www.sec.gov/Archives/edgar/data/1400118/000119312526408224/d96035dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-309334): "Upon completion of Phase 1 clinical trial, plan to consult with regulatory authorities regarding Phase 2 clinical trial design, with goal of initiating Phase 2 clinical trial in 2H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000119312526309334/d141539dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-048971): "Upon completion of Phase 1 clinical trial, plan to consult with regulatory authorities regarding Phase 2 clinical trial design, with goal of initiating Phase 2 clinical trial in 2H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-049015): "Upon completion of Phase 1 clinical trial, plan to consult with regulatory authorities regarding Phase 2 clinical trial design, with goal of initiating Phase 2 clinical trial in 2H 2026" https://www.sec.gov/Archives/edgar/data/1400118/000110465926049015/tm2612794d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059009): "In the near term, we are targeting the second half of 2026 to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne in the U.S. We believe that denifanstat, with its differentiated mode of action, could potentially offer a convenient oral once-daily treatment option for those living with moderate to severe acne." https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059009): "Sagimet plans to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. in the second half of 2026, subject to Investigational New Drug (IND) clearance." https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-048971): "Phase 3 clinical trial in China of our lead molecule denifanstat in moderate to severe acne, we have taken the strategic decision to advance denifanstat in acne for the U.S., starting with a Phase 3 clinical trial expected to begin in the second half of 2026,"" https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_ex99-2.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-048971): "Sagimet plans to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. in the second half of 2026, subject to Investigational New Drug (IND) clearance." https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_ex99-2.htm

### Oct 2026: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: moderate to severe acne in Oct 2026.
- First seen 2026-11-12, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001193125-26-456948): "In October 2026, the Company announced that the first patient has been dosed in AURORA, its pivotal United States Phase 3 clinical trial of denifanstat in adults and adolescents aged 12 years and older with moderate to severe acne." https://www.sec.gov/Archives/edgar/data/1400118/000119312526456948/sgmt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-456948): "In October 2026, we announced that the first patient has been dosed in AURORA, a pivotal United States Phase 3 clinical trial of denifanstat in adults and adolescents aged 12 years and older with moderate to severe acne." https://www.sec.gov/Archives/edgar/data/1400118/000119312526456948/sgmt-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-456948): "Building on the recent successful Phase 3 clinical trials in China of denifanstat in moderate to severe acne, we have advanced denifanstat into AURORA, a pivotal United States Phase 3 clinical trial in adults and adolescents aged 12 years and older with moderate to severe acne, with the first patient dosed in October 2026." https://www.sec.gov/Archives/edgar/data/1400118/000119312526456948/sgmt-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "First patient dosed in AURORA Phase 3 clinical trial in the US for patients with moderate to severe acne in Oct 2026; topline results expected in 2H 2027" https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "First patient dosed in AURORA Phase 3 clinical trial in the US for patients with moderate to severe acne in Oct 2026 November 2026 29" https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex992.htm

### August 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Acne Vulgaris.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07863193 (Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Sagimet Biosciences Inc.." https://clinicaltrials.gov/study/NCT07863193

### Aug to Nov 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Acne Vulgaris.
- First seen 2026-11-12, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07863193 (Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Sagimet Biosciences Inc.." https://clinicaltrials.gov/study/NCT07863193
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "The trial is intended to support a potential U.S. New Drug Application (NDA), with topline data expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027" https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "Denifanstat: Continue enrollment in the U.S. AURORA Phase 3 clinical trial in moderate to severe acne, with topline data expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): "First patient dosed in AURORA Phase 3 clinical trial in the US for patients with moderate to severe acne in Oct 2026; topline results expected in 2H 2027" https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex992.htm

### 2028: topline data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2026-05-12, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059009): "Combined with our existing cash balance, we are well capitalized to fund our programs through 2028 including data readout of our planned denifanstat Phase 3 clinical trial in moderate to severe acne."" https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-059009): "o The Company currently expects that its existing cash and cash equivalents, together with the proceeds from the offering, will fund its acne programs through 2028 and the data readout of the Company's planned denifanstat Phase 3 clinical trial in moderate to severe acne." https://www.sec.gov/Archives/edgar/data/1400118/000110465926059009/tm2614225d1_ex99-1.htm

### mid-2029: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): ""With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA." https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm

### mid-2029: NDA/BLA submission

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-457000): ""With our October equity financing, we are well positioned to fund our programs through mid-2029, including the anticipated Phase 3 denifanstat data readout and the potential submission of an NDA." https://www.sec.gov/Archives/edgar/data/1400118/000119312526457000/d123481dex991.htm

## Same indication

- [1h incubation photodynamic therapy (pdt) (ala-pdt, ameluz®-pdt)](https://sec-api.dev/pdufa/1h-incubation-photodynamic-therapy-pdt-ala-pdt-ameluz-pdt) (BFRI)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/denifanstat.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Denifanstat PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/denifanstat

```bibtex
@misc{secapidev_pdufa_denifanstat_20261116,
  title        = {Denifanstat PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/denifanstat}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_denifanstat_20261116","title":"Denifanstat PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/denifanstat","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
